
## Jennifer W Carlisle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/998184/publications.pdf Version: 2024-02-01



| #  | Article   | IF    | CITATIONS |
|----|---|-------|-----------|
| 1  | An update on the immune landscape in lung and head and neck cancers. Ca-A Cancer Journal for<br>Clinicians, 2020, 70, 505-517.  | 329.8 | 93        |
| 2  | YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell–Inflamed Phenotype. Journal of Thoracic Oncology, 2021, 16, 464-476.   | 1.1   | 93        |
| 3  | Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer. Future Oncology, 2019, 15, 805-816.  | 2.4   | 32        |
| 4  | A banner year for immunotherapy and targeted therapy. Nature Reviews Clinical Oncology, 2019, 16,<br>79-80.   | 27.6  | 24        |
| 5  | Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. Journal of Clinical Oncology, 2022, 40, 3808-3816.   | 1.6   | 19        |
| 6  | Efficacy and safety of immune checkpoint blockade in selfâ€identified Black patients with advanced non–small cell lung cancer. Cancer, 2020, 126, 5040-5049.  | 4.1   | 12        |
| 7  | Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer:<br>ALCHEMIST chemo-IO (ACCIO). Immunotherapy, 2021, 13, 727-734.  | 2.0   | 11        |
| 8  | How I treat older patients with acute myeloid leukemia. Cancer, 2018, 124, 2472-2483.   | 4.1   | 9         |
| 9  | Integrating Genetic and Genomic Testing Into Oncology Practice. American Society of Clinical<br>Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e259-e263.  | 3.8   | 6         |
| 10 | The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma. Expert Opinion on Investigational Drugs, 2018, 27, 163-170.  | 4.1   | 5         |
| 11 | Improving outcomes for brain metastases in EGFR mutated NSCLC. Translational Lung Cancer Research, 2019, 8, S355-S359.  | 2.8   | 5         |
| 12 | Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, and Proteolysis-Targeting Chimeras: The<br>Pharmacology of Cutting-Edge Lung Cancer Therapies. American Society of Clinical Oncology<br>Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e286-e293. | 3.8   | 2         |
| 13 | Considerations for cancer immunotherapy biomarker research during COVID-19. Endocrine-Related Cancer, 2020, 27, C1-C8.  | 3.1   | 0         |